Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

Presentation

New Developments in Topical and Oral Acne Treatments, Combination Therapies, and Challenges in Dermatology Innovation

Description

The speaker reviewed recent acne treatment developments, noting that progress has been slower than in other dermatology areas and emphasizing the need for new chemical entities and better innovation. A new oral fatty acid synthase inhibitor, developed from liver studies, showed marked reductions in sebum and acne lesions with manageable side effects such as dry eye and dry skin, suggesting it could become a future game-changer. The talk also highlighted clascoterone, a topical androgen receptor inhibitor that reduces sebum and inflammatory cytokines, works well on its own and in combination with adapalene or clindamycin/benzoyl peroxide, and appears effective across skin-of-color patients without harming the skin barrier. Trifarotene was discussed not only as an acne retinoid but also for improving post-inflammatory hyperpigmentation and acne scarring, particularly important for patients with skin of color. A new triple-combination topical gel containing adapalene, clindamycin, and benzoyl peroxide showed strong efficacy and tolerability, including in truncal acne. The speaker also addressed concerns about benzoyl peroxide and benzene formation, arguing that formulation and storage conditions matter more than sensational headlines. Finally, he criticized the growing influence of cosmetic marketing, prior authorization burdens, and payer barriers, warning that these forces may be limiting real dermatologic innovation and pushing clinicians away from patient care.

View more

Conclusions

The presentation suggests that acne research is currently producing few new therapies overall, partly because regulatory and reimbursement barriers are slowing innovation and clinical adoption.
Oral denifanstat appears to be a promising new acne treatment because it substantially lowers sebum lipids and improves inflammatory and total lesion counts with acceptable short-term safety.
Clascoterone is presented as an effective topical antiandrogen that reduces sebum and inflammatory signaling while remaining skin-local and generally well tolerated.
Clascoterone seems to work well in combination with standard acne therapies such as adapalene, clindamycin, and benzoyl peroxide, suggesting value as part of combination regimens.
Trifarotene appears to offer benefits beyond acne clearance by improving post-inflammatory hyperpigmentation and reducing acne scarring, especially important for patients with skin of color.
The new triple-combination topical therapy with adapalene, clindamycin, and benzoyl peroxide appears to outperform older dual therapy while maintaining tolerability.
Concerns about benzoyl peroxide turning into dangerous benzene are framed as being strongly influenced by product formulation, temperature, and packaging rather than simple room-temperature storage.
The evidence presented indicates that benzoyl peroxide products do not meaningfully generate benzene under normal room-temperature conditions, and media alarm may overstate the risk.
A natural or once-weekly sponge-based topical treatment may offer modest benefit for acne, but the placebo effect in topical acne studies remains high.
The speaker argues that while moisturizers and cosmetics can support skin care, prescription treatments are still needed and dermatology risks drifting toward cosmetic retail unless clinicians continue to prioritize evidence-based medical care.

Falchook et al., 2021, EClinicalMedicine.
ASC40-303, Ascletis final TFLs, Figure 14.2.1.1.2.
ASC40-303, Ascletis final TFLs, Figure 14.2.5.11.
ASC40-303, Ascletis final TFLs, Figure 14.2.5.9 and 14.2.5.12.
Rosette C, Agan FJ, Mazzetti A, Moro L, Geronem? J Drugs Dermatol. 2019;18(5):412-418.
Ferraboschi P. et al., Med Chem Commun. 2014;5:904-914.
Del Rosso JQ et al., J Drugs Dermatol. 2020;19(3):30-35.
Rosette C et al., J Drugs Dermatol. 2019;18(5):412-418.
DMT310, a novel once-weekly topical treatment for patients with moderate-to-severe acne vulgaris: Results of a phase 2b randomized, double-blind, placebo-controlled trial, PMID 37295506, DOI 10.1016/j.jaad.2023.05.070.#10.1016/j.jaad.2023.05.070
The Role of Formulation in Benzene Formation in Benzoyl Peroxide Products.#10.1001/jamadermatol.2024.6443
Administrative Burden and Costs of Prior Authorizations in a Dermatology Department.#10.1001/jamadermatol.2020.1852